Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2022

## Cp\*Co<sup>III</sup>-catalyzed formal [4 + 2] cycloaddition of 2-phenyl-1*H*-imidazoles to afford imidazo[1,2-c]quinazoline derivatives

Deyu Wu,<sup>a,b</sup> Zhengqiang Liu,<sup>a,b</sup> Yiting Chang,<sup>a,b</sup> Jiajing Chen,<sup>a,b</sup> Haixiang Qi,<sup>a,b</sup> Yi Dong,\*a,b,c Heng Xu\*a,b

- <sup>a</sup> State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- <sup>b</sup> Beijing Key Laboratory of Active Substances Discovery and DrugabilityEvaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- <sup>c</sup> State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medcial University, Guiyang 550014, China.


E-mail: dongyi@imm.ac.cn; xuheng@imm.ac.cn

## Table of cotent

H/D exchange experiment	S1
KIE experiment	S1
Copies of NMR spectra of products	S2


## H/D exchange experiment


A mixture of  $[CoCp*(CO)I_2]$  (15.0 mol%), AgSbF<sub>6</sub> (30 mol%) and 2-phenyl-1*H*-imidazole **1a** (0.2 mmol) in 2.0 mL DCE and 0.5 mL  $[D_4]$ -MeOD was heated at 120°C, and stirred overnight. Then the reaction mixture was cooled to room temperature and filtered, the filtrate was concentrated and the residue was purified with preparative TLC to afford **1a/[D]-1a** (24 mg).





## **KIE experiment**


A mixture of  $[CoCp^*(CO)I_2]$  (15.0 mol%), AgSbF<sub>6</sub> (30 mol%) and 2-phenyl-1*H*-imidazole **1a** (0.2 mmol) or deuterated **[D]-1a** (0.2 mmol) and 3-phenyl-1,4,2-dioxazol-5-one **2a** (0.3 mmol) in 2.0 mL DCE was heated at 120°C for 45 min. Then the reaction mixture was cooled to room temperature and filtered, the filtrate was concentrated and the residue was purified with preparative TLC to afford the desired product **3** (6.5 mg) or **[D]-3** (5 mg). KIE  $\approx$  1.3




































































/146931 144379 /141.263 /130.088 /12.8431 /12.8431 /12.8431 /12.8431 /13.159

77.335 77.080 76.826 -21.555


--0.002











170 160 150 140 130 120 110 100 fl (ppm)








































4.5 4.0 3.5 3.0

8.00 4.00-1 5.00-1

1.00-I

